Monoclonal antibodies (MAbs) were complexed to solid matrices and used to purify virus proteins from simian virus 5 (SV5)-infected tissue culture cells, ideally in such a way as to bind equimolar amounts of antigen to antibody. The resulting solid matrixantibody-antigen (SMAA) complexes were then used as immunogens and successfully induced specific humoral and cytotoxic T cell responses. By attaching more than one MAb to the solid matrix and using such complexes to purify the respective proteins multivalent immunization was achieved. Analysis of the cytotoxic T cell response of immunized animals indicated that both surface and internal SV5 structural proteins can act as target antigens. Immunization with SMAA complexes, in the absence of adjuvant, induced higher levels of antibody than the antigen alone precipitated on alum. However, immunization with SMAA complexes resulted in relatively less antibody being produced to the antigenic determinant through which the protein is coupled, via antibody, to the SMAA complex compared with the amount of antibody produced against other antigenic determinants on that protein. The particulate solid matrix used to form the SMAA complexes in most of the experiments was a 'fixed' and killed suspension of the Cowan A strain of Staphylococcus aureus, although preliminary results indicated that Protein A-Sepharose could also be used as a solid matrix. Prior immunization with S. aureus alone did not reduce the level of the immune response to the appropriate antigen on subsequent immunization with S. aureus-antibody-antigen complexes. In fact on immunization of mice with these complexes the level of antibody produced to the S. aureus matrix itself was less when S. aureus-antibody-antigen complexes were used as immunogens than when S. aureus or S. aureus-antibody complexes were used. Furthermore, rabbits immunized with S. aureus-mouse MAbantigen complexes showed a vigorous immune response to the antigen.
INTRODUCTION
Virus diseases are controlled through primary health care and vaccination. While the majority of vaccines currently in use are based on either whole killed or live attenuated viruses it is to be expected that many future vaccines will be multivalent subunit vaccines based on proteins and immunization schemes capable of inducing both humoral and cell-mediated immunity. Two of the major problems that need to be overcome in the development of subunit vaccines are how to purify the proteins of interest and how to present them to the immune system so as to induce a protective immune response. Many of the conventional methods employed to purify proteins, including immuno-affinity column chromatography, often require the use of strong denaturing conditions which may result in the loss of antigenicity of the protein of interest. Once purified the proteins then have to be either mixed with adjuvants (many of which are unacceptable for use in man because of their damaging side-effects; Adams, 1985) or incorporated into protein micelles, virosomes or immune-stimulating complexes (iscoms) before a strong immune 0000-8441 © 1988 SGM response will be made to the immunizing protein. Incorporation of virus proteins into iscoms appears to be particularly promising as an alternative to conventional adjuvants for use with purified proteins (for review see Morein et al., 1987) . However, even in the production of iscoms the virus proteins have to be purified and the formation of the iscoms (which again require purification) relies upon the presence of appropriate hydrophobic determinants on the protein of interest. In this paper we propose an alternative immunization scheme in which monoclonal antibodies (MAbs) attached to solid matrices may be used to purify specific virus proteins and the resulting solid matrix-antibody-antigen (SMAA) complexes can then be used as immunogens.
Antibody-antigen complexes have in the past been used as immunogens for the preparation of antisera of defined specificity (e.g. Watson & Wildy, 1969) . Furthermore, Johansson et al. (1979) produced polyclonal antisera to adenovirus by immunizing rabbits with immuno-affinity beads prepared by purifying adenovirus antigens on beads of Sepharose 4B to which antiadenovirus antibodies (obtained from a rabbit immunized with adenovirus) had been coupled. However, there are a number of major disadvantages in using polyclonal antibodies in such complexes mainly due to the fact that only a minority of antibodies will be directed against the antigen(s) of interest, most antibodies having unknown specificities. The use of MAbs would facilitate the formation of specific complexes of defined composition in which equimolar amounts of antigen could be bound to antibody. Here we examine the ability of SMAA complexes to induce both humoral and cell-mediated responses. We show that SMAA complexes containing the haemagglutinin-neuraminidase (HN), nucleoprotein (NP) or matrix (M) protein of simian virus 5 (SV5) induce both a vigorous humoral and cytotoxic T cell (Tc) response and discuss the potential uses of SMAA complexes as immunogens and vaccines.
METHODS

Cells and viruses.
Vero and BHK ceils (Flow Laboratories) were grown as monolayers in 75 cm 2 tissue culture flasks or in rotating 80 oz Winchester bottles, in Dulbecco's modification of Eagle's tissue culture medium containing 10% newborn calf serum. A human isolate of SV5 (LN; Goswami et al., 1984) was grown and titrated under appropriate conditions in Vero cells using medium containing 2 % calf serum.
Production of SMAA complexes and immunization of mice and rabbits. Staphylococcus aureus-antibody or Protein A-Sepharose-antibody complexes were made by incubating equal volumes of ascitic fluids with 'fixed' and killed suspensions of the Cowan A strain of S. aureus (10% w/v; Kessler, 1975) or a suspension of Protein A-Sepharose (10% w/v) for 4 h at 4 °C. Unbound antibody was removed by suspension and sedimentation (2500g for 3 min) of the complexes three times in phosphate-buffered saline (PBS). Soluble antigen extracts were prepared from SV5-infected BHK cells as previously described . These extracts were then mixed continuously with the solid matrix-antibody complexes (20 ~tl of a 10% w/v solid matrix-antibody complex/2 x 108 cell equivalents of antigen extract), for 4 to 6 h at 4 °C. The resulting SMAA complexes were washed three times by sedimentation (3300 g for 3 to 10 mins) from and resuspension in immune precipitation buffer (20 mM-Tris-HCl pH 7.2, 5 mM-EDTA, 0.5~ NP40, 0.1 ~ SDS and 0.65 M-NaC1) and then twice in PBS. Mice were immunized twice intraperitoneally with 2 to 5 lag of virus proteins (HN, NP or M) coupled to SMAA complexes (as 200 lal aliquots of 0-5~ w/v suspension of the SMAA complexes) either alone or after the complexes had been precipitated on alum (Chase, 1967) . Alternatively, mice were immunized with 2 to 5 lag of immuno-affinitypurified HN protein precipitated on alum. A gap of 3 to 4 weeks was left between the first and second immunizations, and 10 days after the second immunization the mice were bled, the sera collected and stored at -20 °C until required. Rabbits were immunized twice intramuscularly with 20 to 50 lag of the SV5 HN protein in SMAA complexes alone (0.5 ~ w/v suspension of the SMAA complexes) with a gap of 3 weeks between the first and second immunizations. Ten days after the second immunization the rabbits were bled and the sera stored at -20 °C until required.
Preparation of radiolabelled antigen extracts, immune precipitation and SDS-PAGE. The methodology for these techniques has been described elsewhere . To prepare the soluble antigen extracts the immune precipitation buffer used consisted of 10 mM-Tris-HC1 pH 7.2, 5 rr~-EDTA, 0.5~ NP40, 0.1 ~ SDS and 0.65 M-NaC1 . The polypeptides present in immune precipitates were separated by electrophoresis through polyacrylamide slab gels of standard size and thickness (2 mm), the antibody-antigen polypeptides present in SMAA complexes (Fig. 1) were separated on thin (0.4 mm) mini-slab gels using a Uniscience (London, U.K.) mini-vertical electrophoresis system. Neutralization test. Twofold dilutions of sera (100 ~tl), diluted in tissue culture medium containing 2 % calf serum, were incubated at 37 °C for 2 h with 100 ~tl of SV5 (5 × 105 p.f.u./ml). The antibody-virus mixtures were then used to infect Vero cells growing as monolayers in 96-well microtitre plates. After a 2 to 4 h adsorption period the antibody-virus inoculum was replaced with tissue culture medium containing 2% calf serum and the cells were reincubated at 37 °C for a further 24 to 30 h. The cells were then fixed with 5% formol saline, 2% sucrose for 10 min, permeabilized with 0.5% NP40, 10% sucrose for 5 min and washed three times with PBS. The presence of virus protein was detected by incubating the cells with a mixture of MAbs specific for SV5 (as 1/500 dilutions of ascitic fluids), and bound antibody was detected with 12~i.labelled Protein A (Amersham) as described by Randall et al. (1987) .
Radioimmune assays Detection of anti-HN antibody. The radioimmune assay used to detect anti-HN antibody was based on a method described by Randall et al. (1984) with the modification that the nitrocellulose sheets were sandwiched between 84-well Terasaki plates (10 p.1 of diluted sera/well). Immuno-affinity-purified H N was bound to the nitrocellulose (10 to 20 ~tg/7 x 5 cm sheet) and the protein-binding sites on the nitrocellulose were blocked with bovine serum albumin (BSA). Controls were sheets of nitrocellulose that had been reacted with BSA alone. After reaction of sera with the nitrocellulose, bound antibody was detected with ~ 2Si.labelled Protein A and autoradiography (Randall et al., 1984) .
Detection of anti-Protein A antibody. Protein A (Sigma) was bound to nitrocellulose (100 Ixg/7 × 5 cm sheet) and the radioimmune assay performed as described above. Only antibody binding to the Protein A through an antibody/antigen interaction would have free Fc domains capable of subsequently binding lZSI-Protein A.
Competition assays. The radioimmune competition assay has been described in detail elsewhere .
Generation of Tc cells. Spleens were removed from mice 10 days after the second immunization with SMAA complexes. Spleen cells were isolated and restimulated in vitro with SV5-infected spleen cells for 5 days in a manner described for the generation of Tc ceils specific for respiratory syncytial virus (Bangham et al., 1985) . Bulk cultures were restimulated for a further 5 days with SV5-infected spleen cells and the 5 and 10 day cultures were assayed for the presence of Tc cells.
Target cells and cytotoxicity assays. Target cells were P815 mastocytoma cells that had been infected with SV5 at an m.o.i, of 0.5 to 2 p.f.u./cell for 16 to 18 h. Uninfected P815 cells were used as controls for non-specific lysis. A standard 51Cr release assay performed in U-bottomed microtitre plates was employed based on methods described in detail elsewhere (Zweerink et aL, 1977; Bangham et al., 1985) . Tests were set up in triplicate using 104 target cells/well. 
RESULTS
Induction of humoral immune response with S. aureus-antibody-antigen complexes
The immunoglobulin-binding sites on fixed and killed suspensions of S. aureus were saturated with a MAb specific for the HN protein of SV5. The S. aureus antibody complexes were then used to select the HN protein from infected BHK cells so as to obtain equimolar amounts of antigen bound to antibody. This rapid and simple one-step purification procedure resulted in the HN protein being purified to near homogeneity as judged by SDS-PAGE (Fig. 1) . Groups of three mice were immunized twice intraperitoneally with the S. aureus-antibody complexes or with S. aureus-antibody-HN complexes either alone or after the complexes had been precipitated on alum. At the same time another group of three mice was immunized with equivalent amounts of immuno-affinity-purified HN protein precipitated on alum. Three weeks after the second immunization the mice were bled and the resulting sera tested for their ability to precipitate radiolabelled HN protein from soluble antigen extracts of SV5-infected BHK cells. Sera from mice immunized with purified HN or with S. aureus-antibody-HN complexes precipitated the HN protein (Fig. 2) . Sera from mice immunized with S. aureus-antibody complexes failed to precipitate the HN protein (Fig. 2) , demonstrating that antibody is not released from these complexes after immunization in such a way as to affect subsequent results. The amount of antibody specific for the HN protein in the sera from immunized mice was quantified in a radioimmune assay. In such assays higher levels of anti-HN antibodies were detected in mice that had been immunized with the S. aureus-antibody-HN complexes than in [. mice immunized with purified preparations of the HN protein (Fig. 3) . Furthermore, the levels of anti-HN antibody in the sera of mice immunized with S. aureus-antibody-HN complexes were similar whether or not the complexes had been precipitated on alum. (Subsequent immunizations with SMAA complexes were therefore carried out in the absence of alum.) The level of neutralizing antibody in these sera was also measured and in contrast to the results with the radioimmune assay, the neutralizing titres in mice immunized with purified HN precipitated on alum (Fig. 4, rows 1 to 3) , with S. aureus-antibody-HN complexes alone (Fig. 4 , rows 7 to 9), or with S. aureus-antibody-HN complexes precipitated on alum (Fig. 4, rows Fig. 3. Radioimmune assay employed to measure the level of anti-HN antibody in sera from mice immunized with purified HN precipitated on alum (rows 1 to 3), S. aureus-antibody-HN complexes alone (rows 4 to 6) or S. aureus-antibody-HN complexes precipitated on alum (rows 7 to 9). Sera from immunized mice were diluted initially 1 in 20 and thereafter by doubling dilutions in PBS containing 1% BSA and reacted with nitrocellulose sheets to which purified HN (a) or BSA alone (b) had been previously coupled. Bound antibody was detected with 125I-labelled Protein A and autoradiography.
the MAb (SV5-HN-4a) used to bind the HN protein in the S. aureus-antibody-HN complexes neutralizes SV5 very efficiently . These results could therefore be explained if there were proportionally lower levels of antibody produced against the antigenic determinant defined by MAb SV5-HN-4a in mice immunized with S. aureus-antibody-HN complexes than in mice immunized with purified preparations ofthe HN protein.
To explore this possibility we measured the ability of the various sera to compete with the binding of MAb SV5-HN-4a in radioimmune competition assays. These results showed that sera taken from mice immunized with purified H N precipitated on alum had higher levels of antibody to the antigenic determinant defined by the MAb SV5-HN-4a than did the sera of mice immunized with S. aureus-antibody-HN complexes (Fig. 5) .
Induction of Tc cells by S. aureus-antibody-antigen complexes
A Tc cell assay for SV5 was developed to determine whether immunization with S. aureusantibody-antigen complexes containing SV5 proteins induced Tc cells specific for SV5. The assay developed was based on that used for measuring Tc cell activity against respiratory syncytial virus (Bangham et al., 1985; Pemberton et al., 1987) . Mice were immunized twice intraperitoneally with S. aureus-antibody-antigen complexes containing either HN, NP or M protein of SV5. Ten days after the second immunization the mice were sacrificed and spleens and serum samples collected. Sera from mice immunized with the H N and M proteins precipitated only the respective virus proteins. However, mice immunized with NP also precipitated the phosphoprotein (P) (Fig. 6) . This is consistent with previous observations that NP and P are found in complexes in infected cells and it is difficult to completely purify one protein from the other . To test for Tc cell activity in these mice, spleen cells were stimulated in vitro with SV5 for 5 days and then restimulated for a further 5 days. The ability of the spleen cells stimulated for 5 and 10 days to lyse SV5-infected target cells was measured in 51Cr release assays (Fig. 7) . These results clearly demonstrate that S. aureusantibody-antigen complexes can induce Tc memory cells. S. aureus-antibody-M complexes were particularly effective in inducing Tc cells, less but significant levels of Tc cell activity were induced by S. aureus-antibody-HN and S. aureus-antibody-NP complexes. Higher levels of SV5-specific Tc cell activity were present in the 10 day in vitro restimulated bulk cultures. This may have been mainly because these cultures showed significantly less killing of uninfected target cells (5 to 10 % at a killer to target cell ratio of 50) compared to the 5 day cultures (25 to 40 % at a killer to target cell ratio of 50). 
Multivalent immunization with SMAA complexes
By coupling MAbs with different specificities to the same solid matrix or by mixing different S. aureus-antibody complexes together it may be possible to induce a vigorous immune response to multiple virus proteins at the same time. This potential was demonstrated by mixing together MAbs to the HN, NP, P and M proteins of SV5 before coupling them to S. aureus. The resulting S. aureus-antibody complexes were used to purify the respective virus proteins and mice immunized with these S. aureus-antibody-antigen complexes produced antibodies against all four virus proteins (Fig. 8) . Furthermore, the level of neutralizing activity in mice immunized with multiple virus proteins was similar to that in mice immunized with equivalent amounts of S. aureus-antibody-HN complexes (Fig. 3) . 
Properties oJ the solid matrix for use in SMAA complexes
The experiments described so far involved the use ofS. aureus as the solid matrix. As S. aureus is immunogenic itself we measured the amount of antibody to the Protein A portion of S. aureus in sera from mice immunized with S. aureus-antibody or S. aureus-antibody-HN complexes. These results showed that the amount of antibody produced to S. aureus was less in mice that had been immunized with the S. aureus-antibody-HN complexes than in mice immunized with S. aureus-antibody complexes (Fig. 9) . To determine whether a prior immune response to S. aureus would affect the amount of antibody produced to an antigen upon subsequent immunization with S. aureus-antibody-antigen complexes, mice were immunized twice with S. aureusantibody complexes (above) and subsequently twice with S. aureus-antibody-HN complexes. The amount of anti-HN antibody produced, as determined by measuring the neutralizing activity of the sera, was similar in these mice to that present in the sera of mice immunized twice with S. aureus-antibody-HN complexes only (Fig. 3) .
To determine whether solid matrices other than S. aureus could be used in SMAA complexes, the ability of Protein A-Sepharose-antibody-HN complexes to induce anti-HN antibody was measured. The handling of these complexes was more problematic than the handling of S. aureus-antibody-HN complexes because large aggregates of Protein A-Sepharose formed after the binding of antigen. However, mice immunized with Protein A-Sepharose-antibody-HN complexes made antibody to the HN protein (Fig. 10) , although the level of neutralizing activity in the sera of these mice was less (1/200 to 1/800) than in the sera of mice immunized with equivalent amounts of S. aureus-antibody-HN complexes (1/800 to 1/3200).
Ability of SMAA complexes containing mouse MAbs to immunize rabbits
To determine whether SMAA complexes containing mouse MAbs could induce a specific immune response to a given antigen in non-murine species, a rabbit was immunized twice intramuscularly with S. aureus-mouse MAb-HN complexes. Sera from the rabbit contained high levels of SV5-neutralizing antibody (1/5000) and specifically immune-precipitated the HN protein from soluble antigen extracts of SV5-infected BHK cells (Fig. 10 , lanes 5 and 6).
DISCUSSION
There are a number of important advantages in using SMAA complexes as immunogens over other methods of immunization. Purification of proteins by conventional techniques often results in the proteins, at some stage of the purification procedure, being subjected to strong denaturing conditions which may result in the loss of antigenicity of the protein. Such procedures are often complex, expensive and time-consuming. In the immunization procedure described in this paper the purification of specific virus proteins is very simple and rapid with solid matrix-antibody complexes being used to purify the proteins of interest as well as being part of the immunogen. Apart from the initial solubilization of the virus proteins they are not subjected to any additional denaturation conditions, there being no denaturation stage included to separate the antigen from the antibody. We have shown that S. aureus-antibody-antigen complexes induce a stronger immune response to a given antigen than does the purified antigen alone when precipitated on alum. Furthermore, immunization with SMAA complexes can induce both a vigorous humoral and Tc cell response, both of which may be important in inducing protective immunity to some virus diseases. In fact in the following paper (Randall et aL, 1988) we show that the degree of SV5 replication in the lungs of mice previously immunized with SMAA complexes containing either external or internal virus structural proteins was less than in non-immunized mice. A further potential advantage in using SMAA complexes as immunogens is that different MAbs can be attached to the same solid matrix permitting the purification of multiple virus proteins and the immunization of animals with more than one antigen at the same time. Furthermore SMAA complexes induce a vigorous immune response to appropriate antigens in the absence of adjuvants.
SMAA complexes may act as powerful immunogens because they will be readily phagocytosed by antigen-presenting cells that are involved in the generation of humoral and cell-mediated immunity. Such complexes will also activate the complement system which may enhance the humoral immune response (Klaus, 1988) . For the majority of experiments performed we have used fixed and killed suspensions of the Cowan A strain of S. aureus as the solid matrix. This matrix was chosen because such complexes are of an appropriate size to be phagocytosed by antigen-presenting cells; such suspensions are also economic to prepare, and antibody bound to S. aureus is in the correct orientation to bind antigen. Although we have shown that the immune response to the S. aureus is weak when surrounded by antibody and antigen (presumably because of the masking of the S. aureus by the antibody-antigen complexes) if SMAA complexes were ever used as vaccines in man it may be inappropriate to use S. aureus as the solid matrix. We have shown that it is possible to use solid matrices other than S. aureus to form SMAA complexes, e.g. Protein A-Sepharose. However, the antibody response to an antigen was less when mice were immunized with Protein A-Sepharoseantibody-antigen complexes than when immunized with S. aureus-antibody-antigen complexes. This may have been because the Protein A-Sepharose beads were larger than the S. aureus and the Protein A-Sepharose complexes may have been less efficiently phagocytosed by antigen-presenting cells than were the S. aureus complexes. Also, large aggregates of Protein ASepharose-antibody-antigen complexes formed during the binding of the antigen and this did not happen to the same extent when S. aureus-antibody-antigen complexes were formed. We therefore envisage the future design of solid matrices of optimal size and of defined antigenicity for use in the formation of SMAA complexes as immunogens. Compounds or antigens might also be incorporated into the design of such solid matrices to enhance the immune response.
The use of MAbs in the formation of SMAA complexes means that there is a weaker immune response to the antigenic determinant on a protein through which the protein is coupled, via antibody, to the SMAA complex. This problem can be overcome by using more than one MAb (recognizing different antigenic determinants on a protein) to bind the protein to SMAA complexes or by using MAbs that recognize antigenic determinants not involved in inducing protective immunity. Another potential problem in using SMAA complexes is the possible effect of any immune response to the antibody component of the SMAA complex itself. However, mice immunized with such S. aureus-antibody complexes mounted a vigorous immune response to the appropriate antigen when subsequently challenged with S. aureusantibody-antigen complexes. In addition, although rabbits immunized with S. aureus-mouse MAb-HN complexes produced high titres of anti-mouse immunoglobulin they also produced high titres of anti-HN antibody.
The immunization scheme described in this paper can be used for any protein for which there are MAbs available and a ready source of antigen, e.g. tissue culture cells or expression vector systems. We have used this immunization scheme to produce polyclonal antisera to a large number of virus proteins, including herpes simplex virus gD, herpesvirus saimiri 160K, 117K, 85K and IlK proteins and parainfiuenza virus type 2 HN protein (R. E. Randall & D. F. Young, unpublished results) . In many of these cases we did not bind equimolar amounts of antigen to antibody when forming the SMAA complexes and yet even when the ratio was as low as 1 to 10 we always obtained precipitating antibody to the immunizing antigen.
Immunization with SMAA complexes may have many potential practical uses, for example, evaluation of the ability of specific virus proteins to induce protective immunity (see Randall et al., 1988) or immunization of mice for the production of a bank of MAbs to specific proteins for which only a few MAbs are available. However, we also suggest that the concept of using SMAA complexes as immunogens should be developed and evaluated for potential production of multivalent subunit vaccines for use in both man and animals. While it may not be appropriate to use mouse MAbs to present virus proteins to humans we have shown that S. aureus-mouse MAb-antigen complexes can induce a vigorous immune response in rabbits to the appropriate
